Loading
Molecular Imaging / Prostate Cancer · Journal article
Bioactive Materials · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a first preclinical evaluation of PSMA-targeted nanobubbles for ultrasound contrast imaging of prostate cancer in an orthotopic rabbit model. The agent showed improved peak signal intensity and retention compared to conventional microbubbles and untargeted nanobubbles, with exploratory evidence that kinetics may track tumor viability, but results are limited to a small animal cohort and require clinical translation and validation.
Preclinical in vivo orthotopic animal model study with controlled comparisons. Immunosuppressed New Zealand White rabbits bearing orthotopic PC3pip-GFP prostate cancer xenografts.. Intervention: PSMA-targeted lipid-shelled perfluorocarbon nanobubbles (PSMA-NBs) administered via transabdominal ultrasound imaging.. Compared with: Clinically approved microbubbles (Lumason®) and untargeted plain nanobubbles (Plain-NBs) using identical imaging protocols.. Not explicitly stated in provided text..
PSMA-NBs exhibited 1.60-fold higher peak intensity in tumor core and 1.50-fold higher in rim compared to microbubbles Mean transit time (MTT) was 4.20 to 5.40-fold higher in PSMA-NBs versus microbubbles for up to 10 minutes in tumor and peritumoral areas PSMA-NBs showed 21% improvement in MTT overall in rim and peritumoral areas compared to plain nanobubbles
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical work demonstrates potential for PSMA-targeted nanobubbles to enhance ultrasound-based prostate cancer characterization beyond currently approved microbubbles. However, translation to human clinical use remains speculative; further validation in larger preclinical cohorts and eventual clinical trials would be required before clinical adoption.
First-in-vivo preclinical study of a novel PSMA-targeted nanobubble contrast agent in an orthotopic rabbit model, demonstrating proof-of-concept with exploratory endpoints constrained by small cohort size and non-specific histologic validation.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work demonstrates potential for PSMA-targeted nanobubbles to enhance ultrasound-based prostate cancer characterization beyond currently approved microbubbles. However, translation to human clinical use remains speculative; further validation in larger preclinical cohorts and eventual clinical trials would be required before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The localization of prostate cancer by ultrasound remains limited by the lack of B-mode conspicuity and the confinement of clinically approved microbubbles (MBs) to the vasculature. This precludes differentiating viable tumor, necrotic tissue, and margin-associated disease. We investigated prostate-specific membrane antigen (PSMA)-targeted lipid-shelled perfluorocarbon nanobubbles (PSMA-NBs) in an orthotopic rabbit model using a clinical contrast-enhanced ultrasound (CEUS) system. We implanted PSMA-positive PC3pip-GFP tumors into the prostates of immunosuppressed New Zealand White rabbits and performed transabdominal imaging with PSMA-NBs, MBs, and Plain-NBs using identical protocols. To address tumor heterogeneity and ultrasound boundary ambiguity, regions of interest were defined from baseline B-mode images and segmented into the tumor core, rim, and a peritumoral area. Pixel-wise parametric and decorrelation time (DT) maps were generated and compared with whole-slide histology (H&E) and, in an exploratory and non-specific analysis, with PSMA IHC. Compared to MBs at the doses used, PSMA-NBs exhibited higher peak intensities in the tumor core and rim (1.60-fold and 1.50-fold, respectively) and improved retention (mean transit time [MTT]: 4.20 to 5.40-fold higher) for up to 10 min in the tumor and peritumoral areas. In an exploratory analysis constrained by cohort size, PSMA-NB kinetics, notably MTT, tracked histology-defined tumor viability, and DT mapping showed spatially heterogeneous retention at the tumor periphery. Compared to Plain-NBs, PSMA-NBs also exhibited improved retention (MTT +21% overall) in the rim and peritumoral areas. This study demonstrates the potential of PSMA-NBs to characterize prostate cancer by molecularly targeted CEUS beyond that achieved with MBs at the doses used.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.